Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £13 | £26 | £13 | £15 |
| - Cash | £0 | £1 | £3 | £7 |
| + Debt | £3 | £3 | £3 | £0 |
| Enterprise Value | £16 | £28 | £14 | £8 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Gross Profit | -£1 | -£1 | -£3 | -£0 |
| % Margin | – | – | – | – |
| EBITDA | -£5 | -£6 | -£3 | -£2 |
| % Margin | – | – | – | – |
| Net Income | -£6 | -£7 | -£4 | -£5 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.7 | -2.37 | -1.62 | -2.64 |
| % Growth | 28.3% | -46.3% | 38.6% | – |
| Operating Cash Flow | -£4 | -£6 | -£3 | -£3 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£1 |
| Free Cash Flow | -£4 | -£6 | -£3 | -£3 |